Phenibut for Health & Longevity

Created on 11/01/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Phenibut, a calming drug prescribed in Russia for anxiety, insomnia, fatigue and dizziness and sold online for calm and focus, has modest support from studies lacking placebo or healthy adults; aging effects are unknown. Tolerance can develop within weeks, stopping heavy daily use can bring severe withdrawal, and overdoses, especially with alcohol or sedatives, can cause coma. Brief, low-dose, infrequent pharmaceutical use sits at the lower end of documented risk. (Full Review)

Protocol

Labeled single dose
20–750 mg per dose
Adults, with or without food; prescribed by a physician in Russia
Trial regimens
250 mg three times daily
For three to six weeks, or 500 mg three times daily for 21–60 days
Daily ceiling
2.5 g/day maximum
Russian fact sheets; the Latvian review cites 0.25–2 g/day as the recommended range
Time to effect
Fatigue & dizziness
Over 60 days
500 mg/day reduced both more than betahistine
Anxiety
3 weeks
Scores fell with 750 mg/day, no control group; acute calming after a single dose not measured in trials
Sleep
4 weeks
Subjective sleep improved in adults aged 60–70, without an untreated group

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • People with current or past substance use disorder
  • People taking opioids, hypnotics or other central nervous system depressants
  • People with liver insufficiency or erosive or ulcerative gastrointestinal disease
  • People with known hypersensitivity to phenibut
  • People with seizure disorders
  • People with reduced kidney function
  • Drivers and machine operators during use
Key Interactions
  • Antiepileptics (gabapentin, pregabalin)
  • Antipsychotics (quetiapine, olanzapine)
  • Antiparkinsonian drugs (levodopa, pramipexole)
  • Benzodiazepines (alprazolam, diazepam)
  • Alcohol (avoid)
Theoretical (inferred from mechanism)
  • Baclofen
  • Over-the-counter sedating antihistamines (diphenhydramine, doxylamine)
  • Sedating supplements (kava, valerian, melatonin)
  • Kratom and cannabis (THC)
  • Gamma-hydroxybutyrate (GHB) and sodium oxybate

Risk & Side Effects

  • High:
  • Medium: Daytime Somnolence & Impaired Driving
  • Low: Tolerance, Dependence & Withdrawal Syndrome; Central Nervous System Depression, Coma & Death in Overdose; Agitation, Anxiety, Psychosis & Delirium; Nausea, Headache, Dizziness & Skin Rash; Liver Effects at High Doses
  • Speculative: Falls in Older Adults; Undisclosed Exposure From Adulterated Products

Monitoring

Marker Target Why
ALT 7–56 U/L Safety check: rising values stop use
AST 10–40 U/L Safety check: rising values stop use
Complete blood count with differential Hemoglobin 13.5–17.5 g/dL men, 12.0–15.5 g/dL women; white cells 4.5–11.0 × 10⁹/L Safety check: abnormal counts stop use
Serum creatinine 0.7–1.3 mg/dL men, 0.6–1.1 mg/dL women Safety check: impaired clearance changes dose

Cadence: Baseline liver function, blood count and kidney function before a course; liver enzymes and blood count at 4 weeks, then every 1–3 months while use continues; kidney function every 3–6 months; symptom ratings weekly during the first month, then monthly.

Qualitative Assessment

  • Anxiety level: self-rated daily tension and worry, compared with baseline
  • Sleep quality: time to fall asleep, night awakenings and morning refreshment
  • Daytime alertness: drowsiness, reaction time and fitness to drive the morning after evening doses
  • Fatigue: physical and mental energy across the day
  • Tolerance signals: gradual dose escalation, shorter duration of effect, or craving
  • Withdrawal signals: irritability, insomnia or tremor after a delayed or missed dose